Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

Bayer, Orion prep challenge in prostate cancer market

resistant prostate cancer (CRPC), as they prepare to take on rival therapies from Johnson &Johnson and Pfizer/Astellas. ... Orion and Bayer have another phase 3 trial on the go in patients with metastatic hormone-sensitive prostate cancer (mHSPC) –

Latest news

  • Merck puts prostate cancer firmly in Keytruda’s sights Merck puts prostate cancer firmly in Keytruda’s sights

    In the Keytruda plus Lynparza arm, 12% of patients had a 50% or greater reduction in PSA, a biomarker which is elevated in prostate cancer. ... prostate cancer, which is considered a cold tumour with few tumour-infiltrating lymphocytes.”.

  • J&J earnings top expectations, but feels the squeeze in US J&J earnings top expectations, but feels the squeeze in US

    Prostate cancer drug Zytiga sales fall 12.7% in the US thanks to new generic competition, while pulmonary hypertension medicine Tracleer declined by around 25% for the same reason. ... The company is hoping to retain a share of the prostate cancer market,

  • J&J’s Erleada cleared for early prostate cancer in Europe J&J’s Erleada cleared for early prostate cancer in Europe

    For patients however, it means a new choice of treatments for a critical stage of prostate cancer that currently has few treatment options. ... One of the key goals in prostate cancer treatment is to delay the disease from spreading,” commented Simon

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    studies of NKTR-214 in front-line and second-/third-line non–small-cell lung cancer (NSCLC) in the second-quarter, and are now working on 20 indications across nine tumour ... Combination trials in head and neck cancer and castration-resistant prostate

  • Generic threat looms to J&J’s blockbuster Zytiga in US Generic threat looms to J&J’s blockbuster Zytiga in US

    Impact could also be felt by Pfizer. A US appeals court has turned down an appeal by Johnson &Johnson to block generic sales of its prostate cancer therapy Zytiga, freeing rival ... J&J has been trying to expand its prostate cancer franchise with the

More from news
Approximately 50 fully matching, plus 273 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    year. 10. Erleada – the next generation prostate cancer treatment. Johnson &Johnson gained FDA approval for Erleada in February 2018, and it just got the go ahead in Europe as the first ... In patients with non-metastatic CRPC, there is a high unmet

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    This saw phase 3 flops of drugs for stroke, prostate cancer and depression – failures that dented confidence in the firm as patent expiries for its blockbusters Crestor and Nexium loomed on ... People who have BRCA gene mutations have an increased risk

  • Deal Watch October 2018

    The product is in development for the treatment of metastatic castration‐resistant prostate cancer and is in phase 3 trials. ... prostate cancer. Acquisition. $2.1B. Acquisition. Dermocosmetic, cosmetic and skin care products.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies.

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Billy Connolly received the news of his diagnosis for dementia and prostate cancer on the same day:. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht,” he

More from intelligence
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 6 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...

Infographics